SANKYO CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,644 JPY | -1.35% |
|
-0.57% | -0.07% |
| Apr. 08 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
| Apr. 08 | AstraZeneca's, Daiichi's Enhertu receives US FDA approval | AN |
| Sales 2024 * | 201B 1.29B | Sales 2025 * | 198B 1.28B | Capitalization | 365B 2.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 52.51B 338M | Net income 2025 * | 52.26B 336M | EV / Sales 2024 * | 1.82 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.84 x |
| P/E ratio 2024 * |
7.63
x | P/E ratio 2025 * |
7.37
x | Employees | 864 |
| Yield 2024 * |
5.3% | Yield 2025 * |
5.44% | Free-Float | 46.97% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.35% | ||
| 1 week | -0.57% | ||
| Current month | -1.82% | ||
| 1 month | -3.10% | ||
| 3 months | -11.45% | ||
| 6 months | +29.98% | ||
| Current year | -0.07% |
1 week
1 604.50
1 670.00
1 month
1 600.501 723.00
Current year
1 595.601 921.80
1 year
1 074.001 921.80
3 years
515.401 921.80
5 years
513.201 921.80
10 years
513.201 921.80
| Managers | Title | Age | Since |
|---|---|---|---|
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 86-03-31 |
| Chairman | 71 | 77-03-31 | |
Sou Busujima
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 77-03-31 | |
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 86-03-31 |
Ichiro Tomiyama
COO | Chief Operating Officer | 66 | 86-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.78% | 9 M€ | +16.41% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1,644 | -1.35% | 339 200 |
| 24-04-24 | 1,666 | +0.97% | 1,043,900 |
| 24-04-23 | 1,650 | +0.49% | 831,300 |
| 24-04-22 | 1,642 | +0.61% | 1,447,400 |
| 24-04-19 | 1,632 | -1.27% | 1,139,600 |
Delayed Quote Japan Exchange, April 25, 2024 at 12:01 am EDT
More quotes
Sankyo Co Ltd is a Japan-based company mainly engaged in the pachinko machine related business, pachislot machine related business, and replenishment equipment related business. The Company operates through three business segments. The Pachinko Machine-related Business segment is engaged in the manufacture and sale of pachinko machines and gauge boards for pachinko machines, the sale of related parts, and acquisition of royalties income related to pachinko machines. The Pachislot Machine-related Business segment is engaged in the manufacture and sale of pachislot machines, the sale of related parts, and acquisition of royalties income related to pachislot machines. The Supply Equipment-related Business segment is engaged in the sale of pachinko/pachislot supply equipment, card system equipment, hall equipment peripheral equipment. It also provides mobile content services, real estate rental, sales of general molded parts.
Sector
Casinos & Gaming
Calendar
2024-05-08
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1,666
JPY
Average target price
1,928
JPY
Spread / Average Target
+15.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.07% | 2.34B | |
| +13.93% | 8.5B | |
| -23.96% | 729M | |
| +10.12% | 697M | |
| +31.38% | 366M | |
| +3.44% | 340M | |
| +5.37% | 340M | |
| +16.81% | 185M | |
| +28.00% | 98.85M | |
| -28.70% | 62.77M |
- Stock Market
- Equities
- 6417 Stock
